INTRODUCTION
Female genital tracts, particularly human vaginal mucosa, have long been attractive as a potential site for mounting protective immunity against sexually transmitted pathogens, including viruses and bacteria. 1, 2 However, the vaginal mucosa, a site constantly exposed to foreign antigens, is a unique tolerogenic microenvironment that can control unwanted types of immune responses. 1, [3] [4] [5] Nonetheless, the immunology of the human vagina remains poorly understood.
Dendritic cells (DCs) are major antigen-presenting cells (APCs). DCs can direct host immune responses toward either immunity or tolerance. 6 Subsets of DCs residing in one particular tissue, as well as DCs in draining lymph nodes, have diverse but specialized functions in directing host immune responses. 7 DCs also display functional plasticity in response to microbial pathogens. 8 Early studies in animals showed that vaginal mucosa is covered with stratified squamous epithelium 2, 3, 9 and shares several common features with the skin. Langerhans cells (LCs), which do not have Birbeck granules, 10 are found in the epithelium and CD11c þ DCs in the lamina propria (LP).
1,2 DC-SIGN þ CCR5 þ LP-DCs were also reported in animals. 11, 12 Although the presence of LCs in the human vaginal epithelium has been reported, 13 no further information is available. Moreover, immunological functions of DCs localized in the human vagina remain unknown.
In this study, we first characterized subsets of DCs and macrophages (Mf) that are localized in the human vaginal mucosa by assessing their phenotypes and morphology. We then tested the functional specialties of the individual subsets of APCs in directing CD4 þ and CD8 þ T-cell responses by measuring the quantity and quality of T-cell responses. We also tested the ability of the individual APC subsets for inducing chemokine receptors that are detected on T cells in the vaginal mucosa. To address functional plasticity of the vaginal APC subsets, we first assessed the expression levels of Toll-like receptors (TLRs). We were then able to examine T-cell responses induced by the APC subsets activated with different microbial products and their synthetic analogs. Data from this study help us understand how the immune responses in the human vagina are induced and controlled in a steady state, as well as during microbial infections. This study also provides fundamental information for the design of effective mucosal vaccines against many sexually transmitted diseases that still cause a major public health burden worldwide.
RESULTS

Human vaginal mucosa contains four major subsets of myeloid-originated APCs
Mucosal tissues were enzymatically digested and stained with 7-aminoactinomycin D and the indicated antibodies (Abs) (Figure 1a (Figure 1b) , suggesting their classification as DCs. CD1c
À CD14 þ cells contain large vacuoles in the cytoplasm, which is an Mf characteristic. Large fractions of the cells in group V express CD34 (77.41 ± 11%) and CD54 (59.83 ± 9.3%) ( Figure 1c and Supplementary  Figure 1a online). Only 6.5% of them express either CD66 or pan-cytokeratin that are known to be expressed on epithelial cells. E/P selectin is expressed 31 ± 3.3% of the cells. The expression levels of CD34, CD54, E/P selectin, and CD123 are higher than those of CD66 and E-cadherin ( Supplementary  Figure 1b online) . Therefore, the cells in group V are mainly composed of endothelial cells, but with epithelial cells that can constitutively express major histocompatibility complex class II. 14, 15 
CD207
þ cells are mainly found in the epithelium, whereas the other three subsets (CD1c þ CD14 À , CD1c þ CD14 þ , and CD1c À CD14 þ ) are in the LP (Figure 1d and Supplementary  Figure 2a online The four APC subsets were further characterized by examining their phenotypes (Figure 1e ). CD207 þ cells express both CD1a and E-cadherin, which is expressed on LCs. 16 LCs, as well as the CD1c þ CD14 À LP-DCs (CD14 À LP-DCs) and CD1c We next tested whether different subsets of the APCs express distinct patterns of chemokine receptors and b7-integrin (Figure 1g ). CCR2, a homing receptor for monocytes and Mf, 18 is expressed on Mf but not on the vaginal DCs. CCR5 and CXCR4, coreceptors for HIV, are expressed on LCs as well as on the other three subsets of APCs. 19 Interestingly, LP-DCs and Mf express increased levels of CCR5 and CXCR4 compared with LCs. Both LCs and LP-DCs exhibit similar levels of CCR6 that is also expressed on intestinal DCs. 20 b7-integrin is detected only on LCs and LP-DCs, but not on Mf. Both CCR4 and CX3CR1 were similarly expressed on the four subsets of APCs. CCR7 and CD103 were not detected on the surface of the vaginal APC subsets (data not shown). Taken together, the four subsets of vaginal APCs express shared and distinct patterns of surface receptors, including costimulatory molecules and chemokine receptors. This suggested that each subset of the APCs might possess common as well as distinct functions in directing the immune responses in the vagina.
Functional specialties of the vaginal APC subsets in directing CD4
þ T-cell responses 5,6-Carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled allogeneic naïve T cells were cocultured for 7 days with different numbers of the APC subsets, and then CD4 þ T-cell proliferation and intracellular cytokine expression were assessed. Vaginal DCs induced greater CD4 þ T-cell proliferation than did Mf (Figure 2a (left panel) ). CD14
À LP-DCs and LCs induced similar levels of naïve CD4 þ T-cell proliferation. However, CD14
þ LP-DCs were less efficient than LCs at inducing CD4 þ T-cell proliferation. The level of CD4 þ T-cell proliferation induced by monocyte-derived dendritic cells (DCs) generated in the presence of IFNa (IFNDCs) (2 Â 10 
HLA-DR
þ CD207 À cells were further divided into four groups based on CD1c and CD14 expression (right panel: 
T cells expressing T-helper type 2 (Th2)-type cytokines as well as tumor necrosis factor (TNF)a than did CD14
þ LP-DCs and Mf. Although Th17 contribute to the protective immunity against mucocutaneous candidiasis [21] [22] [23] and skin dermal-DCs are potent Th17 inducers, 24 none of the vaginal APC subsets induced significant levels of interleukin (IL)-17 þ skin dermal-DCs were potent inducers of IL-21 þ CD4 þ T cells. 25 Furthermore, vaginal LCs and CD14 À LP-DCs induced similar levels of naïve CD4 þ T-cell proliferation, whereas skin LCs were superior to CD1c þ dermal-DCs at inducing naïve CD4 þ T-cell proliferation. 25 The quality of CD4 þ T cells induced by the vaginal APC subsets was further analyzed by the Boolean gating strategy. LCs and CD14 À LP-DCs were able to polarize naïve CD4 þ T cells mainly toward Th2, whereas CD14
þ LP-DCs and Mf polarized them toward Th1 ( Figure 2d ). In all, 62% and 21% of the LC-induced CD4
, respectively. Similarly, 62% and 22% of the CD14 À LP-DCinduced CD4
þ T cells expressed IL-13 and IL-5, respectively. In contrast, 79% and 75% of the CD4 þ T cells induced by CD14
þ LP-DCs and Mf, respectively, expressed
T cells induced with LCs and CD14
À LP-DCs expressed Th2 cytokines, whereas the majority of IFNg 
cells (42%). LCs (19%) and CD14
À LP-DCs (15%) also induced greater percentage of TNFa (Figure 3a) . Notably, the three vaginal DC subsets were equally potent at inducing naive CD8 þ T-cell proliferation, although human skin LCs were superior to dermal-DCs at eliciting CD8 þ T-cell proliferation. À LP-DCs were mainly due to the increased induction of Figure 4c ) express CD103 that could allow T-cell migration or retention in the vagina. [26] [27] [28] [29] More importantly, vaginal DCs and Mf in a less extent were able to induce CD103 on CD4 þ (upper panels, Figure 4d ) and especially CD8 þ T cells (lower panels, Figure 4d ). CD14 þ LP-DCs were less efficient than the other two DC subsets, but more efficient than Mf and IFNDCs at inducing CD103 expression. Fractions of CD4 þ and CD8 þ T cells (lower panels). Taken together, T cells in the vagina express CD103, b7-integrin, CCR4, b7-integrin, and CXCR3. Vaginal APCs can induce these receptors on both CD4 þ and CD8 þ T cells, but individual subsets could display common and distinct functions at inducing these receptor expressions on T cells. TLR1  TLR2   TLR3   TLR4   TLR5   TLR6  TLR7  TLR8   TLR9   RIG-I   MDA-5   TLR10  TLR4   TLR1  TLR2   TLR3   TLR5   TLR6  TLR7  TLR8   TLR9   RIG-I   MDA-5   TLR10   TLR1  TLR2   TLR3   TLR4   TLR5   TLR6  TLR7  TLR8   TLR9   RIG-I   MDA-5   TLR10   TLR1  TLR2   TLR3   TLR4   TLR5   TLR6  TLR7  TLR8   TLR9 and retinoic-acid-inducible protein I, which were minimally expressed in LCs and CD14
À LP-DCs. Compared with the three subsets of DCs, Mf expressed increased levels of TLR1, TLR2, TLR4, and TLR6. It was of note that vaginal DCs express increased levels of TLRs for viral products, whereas Mf express TLRs for both viral and bacterial products.
We next tested the effects of bacterial flagellin (TLR5 ligand), R848 (ssRNA: TLR7/8 ligand), poly-IC (dsRNA: TLR3, melanoma differentiation-associated gene 5, and retinoicacid-inducible protein I ligand) and Escherichia coli lipopolysaccharide (E. coli LPS: TLR4 ligand), on the vaginal APCinduced CD4 þ T-cell responses (Figure 5b ). R848 enhances LC-and CD14
À LP-DC-induced CD4 þ T-cell proliferation (Supplementary Figure 8a Taken together, individual subsets of the vaginal APCs display their own functional plasticity in directing CD4 þ and CD8 þ T-cell responses. None of the stimuli bias the four APC subsets to induce common types of immune responses. Thus, the immune responses, particularly Th1 vs. Th2, in the vagina can be well balanced by distinct but compensatory functions of the individual APC subsets in the vagina.
Both LCs and CD14
À LP-DCs are potent inducers of IL-22-producing CD4
þ T cells IL-22 induces the secretion of antimicrobial products and contributes to the recovery of epithelial cells. [34] [35] [36] [37] As shown in Figure 6a , both LCs and CD14 À LP-DCs display similar ability to induce IL-22 þ CD4 þ T-cell responses, although LCs in human skins are superior to dermal-DCs. 38 Data from six independent experiments are summarized in Figure 6b .
þ T cells were further analyzed for IFNg, IL-17, and IL-5 expression (Figure 6c) . À LP-DCs, CD14 þ LP-DCs, and Mf) that show distinct phenotypes and functions in directing the immune responses in the vaginal mucosa. These APCs are further distinguished from those of other human tissues, including skin 24, 25, 38, 39 and intestine, 40 by displaying distinct functions in directing both CD4 þ and CD8 þ T-cell responses. These characters of the vaginal APCs support a current notion that human vaginal mucosa is an immunologically unique microenvironment that is different from other tissues or organs. 1, 3, 4 Th1, Th2, and Th22 are the major types of immune responses induced by the vaginal APCs. They are not potent inducers of IL-10-producing CD4 þ T cells (data not shown) or Th17, which contribute to the protective immunity in the vagina. [21] [22] [23] All three DC subsets are almost equally capable of inducing IL-21-producing CD4 þ T-cell responses. Foremost, the magnitude of Th1-vs. Th2-type responses can be balanced by distinct but compensatory functions of the individual APC subsets in a steady state. Microbial products and analogs bias the individual subset-driven immune responses. For example, activation of LCs and LP-DCs with R848 resulted in decreased T-cell responses, particularly IL-5-producing T-cell responses. In contrast, R848 enhanced LCs and CD14
None of the microbial products tested in this study was able to activate the four APC subsets to induce the same types of T-cell responses. Studies have shown that intravaginal administration of vaccines can induce certain levels of protective immunity in both animals [41] [42] [43] and humans. [44] [45] [46] However, the development of safe vaccines that can establish protective mucosal immunity, particularly cellular immunity, which is crucial for the protection against intracellular pathogens, in the human vagina still remains as a challenge. 
IL-5
þ CD8 þ T cells is largely unknown, but CD8 þ T cells in the genital tract are thought to be Tc2 or regulatory T cells. 5, 47 For the Th22, both LCs and CD14
À LP-DCs showed a similar ability to induce IL-22 þ CD4 þ and IL-22 þ CD8 þ T cells expressing IFNg or IL-5, which is distinct from skin DCs and IL-22 þ T cells induced with skin DCs. 38 To design more effective vaccines in the future, these features of the vaginal APCs also need to be considered.
aEb7-(or CD103/b7-) integrin expressed on T cells 26, 27 allows lymphocytes to migrate into local mucosal tissues and contributes to their retention within the epithelial layers of the mucosa, 28 especially in the vagina. 27, 29 We demonstrate that fractions of T cells in the human vagina express CD103, CCR4, CXCR3, and b7-integrin. To get further insight of the immunology of human vagina, future studies need to be performed in humans or animals that have similar features that human vagina has. The microenvironments in the vagina of humans and mice are different. First, the two are constantly exposed with different types of antigens. Second, commensal microorganisms in the two are not the same. Thus, APCs localized in the two immune systems could display distinct functions in directing the immune responses in the vaginal mucosa. This can be applied to the immune responses in a steady state as well as during microbial infections. Future studies also need to consider the effects of female hormones. [48] [49] [50] In conclusion, human vaginal mucosa contains four major subsets of myeloid-derived APCs. Each of the subsets displays common as well as unique phenotypes and functions that direct the immune responses in the vagina. Such functional specialties and plasticity driven by the different subsets of the vaginal APCs may have important roles in shaping the vaginal mucosa as an immunologically unique microenvironment. To elicit desired types of adaptive immune responses in the vagina, antigens need to be delivered to the selected APC subset with adjuvants that can further promote the APC-mediated immune responses. Cell phenotypes and morphology. Cell phenotypes were assessed by flow cytometry analysis. Cells were stained with the following Abs and 7-aminoactinomycin D: anti-HLA-DR-AF700, anti-CD1c-AF647, anti-CD1a, anti-CD11c, anti-CD34, anti-CD54, anti-CD83, anti-CD86, anti-CCR6, and anti-E-cadherin from BioLegend (San Diego CA); anti-Langerin phycoerythrin (PE) from Beckman Coulter (Brea, CA); anti-Langerin AF488 (in-house); anti-CD14-eFluor450 (eBiocience, San Diego, CA); anti-CD66, anti-CD123, and anti-b7-integrin Abs from BD Biosciences; anti-E/P selectin, anti-CCR2, anti-CCR4, anti-CCR5, anti-CCR7, and anti-CXCR4 Abs from R&D Systems (Minneapolis, MN); anti-CD163 from BMA Biomedicals (Augst, Switzerland); and anti-CX3CR1 from MBL International (Woburn, MA). Phenotypes of vaginal APCs were analyzed by flow cytometry on an LSR II (BD Biosciences). Anti-CD103 and anti-CCR4 Abs used for T-cell phenotyping were from eBioscience and R&D Systems, respectively.
METHODS
Cell morphology was examined after the Giemsa staining of sorted vaginal APC subsets. Giemsa staining of sorted vaginal APCs was carried out using the Diff-Quik Stain Set according to the manufacturer's protocol (Siemens Healthcare Diagnostics, Erlangen, Germany). Images were acquired using an Olympus BX60 microscope (Olympus, Centre Valley, PA) with Planapo 100 Â /1.4 oil objective and a Nikon DXM1200C digital color camera (Nikon Instruments Inc., Melville, NY) with Nikon NIS Elements F Version 2.30 software (Nikon Instruments Inc.).
APC isolation. Tissues were cut into small pieces approximately 1 cm 2 , and incubated in phosphate-buffered saline containing 2 mM ethylenediaminetetraacetic acid and antibiotic/antimycotic solution overnight at 41C. Epithelium and LP were then separated. LP was cut into smaller pieces (1-5 mm 2 ). Epithelial sheets and LP pieces were incubated for 2 days at 37 1C in RPMI 1640 supplemented with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, L-glutamine, nonessential amino acids, sodium pyruvate, antibiotic/antimycotic, and 10% fetal calf serum. Migratory cells were recovered, filtered consecutively on 100, 70, and 40 mm cell strainers and washed. Cells were stained with 7-aminoactinomycin D, anti-HLA-DR-AF700, antiLangerin-PE, anti-CD1c-FITC (Invitrogen), and CD14-eFluor450. HLA-DR þ cells were gated and then Langerin
þ CD14 þ , and CD14 þ CD1c À cells were sorted by FACS Aria II (BD Biosciences).
Preparation of T cells and monocyte-derived IFNDCs. Peripheral blood mononuclear cells from healthy volunteers were fractionated by elutriation, under a protocol that has been approved by the Institutional Review Board of Baylor Research Institute. IFNDCs were generated by culturing monocytes in serum-free medium (Cellgenix, Freiburg im Breisgau, Germany) supplemented with granulocytemacrophage-colony-stimulating factor (100 ng ml À 1 ) and IFNa (500 U ml À 1 ) (IFNDCs). The medium was replenished with cytokines on day 1 for IFNDCs. IFNa and granulocyte-macrophage-colonystimulating factor were from the Pharmacy at Baylor University Medical Center (Dallas, TX). Naïve (CD45RA þ CD45RO À CCR7 þ ) T cells (purity 499.2%) were sorted on FACS Aria II.
T-cell responses. A total of 1.5 Â 10 5 CFSE-labeled purified naïve T cells were cocultured with 2 Â 10 3 or the indicated number of APCs in RPMI 1640 supplemented with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, L-glutamine, nonessential amino acids, sodium pyruvate, penicillin/streptomycin, and 10% AB serum (GemCell, West Sacramento, CA). In some experiments, vaginal APCs were activated with R848 (2 mg ml À 1 ), flagellin (200 ng ml À 1 ), poly-IC (2 mg ml À 1 ), or E. coli LPS (100 ng ml À 1 ) for 16 h before the addition of T cells. All TLR-L are from Invivogen (San Diego, CA). After 7 days, cells were stained with anti-CD4 APC-Cy7 (BioLegend), anti-CD8 Pacific Blue (BioLegend) and LIVE/DEAD Fixable Dead Cell Stain Kit (Invitrogen), and T-cell proliferation was tested by measuring CFSE dilution. For cytokine expression analysis, T cells were restimulated with 100 ng ml À 1 phorbol 12-myristate 13-acetate (Sigma) and 1 mg ml À 1 ionomycin (Sigma) for 6 h in the presence of GolgiPlug (BD Biosciences). They were then stained with anti-CD4, anti-CD8, LIVE/ DEAD Fixable Dead Cell Stain Kit, and anti-IFNg, anti-IL-5, antiTNFa, anti-IL-13 Abs (all from BioLegend), anti-IL-17, anti-IL-21, and anti-IL-22 Abs (all from eBioscience). Intracellular staining was performed using BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences) according to the manufacturer's protocol.
Immunofluorescence. Cryosections were fixed in cold acetone, dried, and blocked for nonspecific fluorescence with Fc receptor block and background buster (Innovex Biosciences, Richmond, CA). Sections were stained with the indicated Abs and then subsequently stained with 4 0 ,6-diamidino-2-phenylindole (Invitrogen). Digital images were taken using an Olympus BX51 with a Planapo20/0.7 or Planapo40/0.95 objective, a Roper Coolsnap HQ camera (Olympus) and Metamorph software (Molecular Devices, Sunnyvale, CA). FACS-sorted HLA-DR þ CD207 À CD1c À CD14 À cells were fixed in 4% paraformaldehyde and stained with the indicated Abs, and then subsequently stained with 4 0 ,6-diamidino-2-phenylindole. Confocal images were taken with the Leica SP1 (Leica, Buffalo Grove, IL) and Planapo63/1.32 objective. Images were acquired using the same exposures for Ab and isotype staining and identical scaling was applied.
Microarray analysis. RNA was purified following the manufacturer's instructions for the ArrayPure Nano-scale RNA Purification Kit (Epicentre Biotechnologies, Madison, VI). Amplification and labeling was carried out following the manufacturer's instructions for the TargetAmp 2-Round Biotin-aRNA Amplification Kit 3.0 (Epicentre). A total of 750 ng of cRNA was used for hybridization of technical duplicates onto the Illumina Human H12v4 BeadChip. Scanning of the BeadChip was carried out on the iScan (Illumina Inc., San Diego, CA) using the manufacturer's recommended settings. Microarray data were background subtracted and scaled as per the Illumina GenomeStudio V2011.1 GX1.9.0 User Guide. GeneSpring v.7.3 (Agilent Technology Inc, Santa Clara, CA) software was used for unsupervised analysis and data filtering (detection Po0.01 in at least two samples). For each sample, background-subtracted and scaled-intensity values for the probes representing the genes of interest were exported to Excel. Values o10 were converted to 10, and then the intensity average was calculated for biological replicates.
Statistical analysis. Statistical significance was determined using the analysis of variance test or paired t-test using the Prism 5 software (GraphPad Software, La Jolla, CA). Significance was set at Po0.05.
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